Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer

• Material Type: 博士論文
• Title: Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer
• Author/Editor: 赤城, 和優
• Author Heading: 赤城, 和優
• Publication, Distribution, etc.: Elsevier B.V.
• Publication Date: 2024-09-04
• Publication Date (W3CDTF): 2024-09-04
• Alternative Title: 進行非小細胞肺がんに対するドセタキセル併用下のラムシルマブの薬物動態が有効性・生存期間に与える影響について
• Periodical title: Lung Cancer
• No. or year of volume/issue: 178
• Volume: 178
• Pages: 247-253
• ISSN (Periodical Title): ISSN : 0169-5002; EISSN : 1872-8332
• Degree grantor/type: Nagasaki University (長崎大学)
• Date Granted: 2024-09-04
• Dissertation Number: 甲医歯薬第1634号
• Degree Type: 博士(医学)
• Text Language Code: eng
• Subject Heading: Cachexia; Liquid chromatography-mass spectrometry; Non-small cell lung cancer; Pharmacokinetics; Ramucirumab
• Target Audience: 一般
• Note (General): 長崎大学学位論文 学位記番号:博(医歯薬)甲第1634号 学位授与年月日:令和6年9月4日; Author: Kazumasa Akagi, Shigehiro Yagishita, Mayu Ohuchi, Yoshiharu Hayashi, Yuki Takeyasu, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Hiroshi Mukae, Yuichiro Ohe, Akinobu Hamada; Citation: Lung Cancer, 178, pp.247-253; 2023; Nagasaki University (長崎大学), 博士(医学) (2024-09-04)
• Format (IMT): application/pdf
• Source: fulltext; https://nagasaki-u.repo.nii.ac.jp/record/2001541/files/ISYK1634_Akagi.pdf
• Access Restrictions: インターネット公開
• Rights (production): © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
• Related Material (URI): HDL; http://hdl.handle.net/10069/0002001510
• Related Material (DOI): 10.1016/j.lungcan.2023.03.001
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 長崎大学 : 長崎大学学術研究成果リポジトリ

• Summary, etc.: Objectives: Ramucirumab, an anti-vascular endothelial growth factor receptor-2 antibody, has been approved for the treatment of non-small cell lung ca...